4//SEC Filing
Hadar Ilan 4
Accession 0001209191-20-018225
CIK 0001566044other
Filed
Mar 10, 8:00 PM ET
Accepted
Mar 11, 5:56 PM ET
Size
30.4 KB
Accession
0001209191-20-018225
Insider Transaction Report
Form 4
Hadar Ilan
CFO and Country Manager
Transactions
- Award
Stock Options
2020-03-09+57,086→ 57,086 totalExercise: $6.81Exp: 2030-02-24→ Common Stock (57,086 underlying) - Award
Common Stock
2020-03-09+8,339→ 8,339 total - Award
Stock Options
2020-03-09+35,774→ 35,774 totalExercise: $17.40Exp: 2027-01-01→ Common Stock (35,774 underlying) - Award
Stock Options
2020-03-09+116,231→ 116,231 totalExercise: $8.81Exp: 2027-08-08→ Common Stock (116,231 underlying) - Award
Stock Options
2020-03-09+20,789→ 20,789 totalExercise: $10.81Exp: 2028-02-27→ Common Stock (20,789 underlying) - Award
Common Stock
2020-03-09+69,012→ 77,351 total - Award
Stock Options
2020-03-09+3,239→ 3,239 totalExercise: $3.25From: 2020-03-09Exp: 2024-03-31→ Common Stock (3,239 underlying) - Award
Stock Options
2020-03-09+14,291→ 14,291 totalExercise: $9.22From: 2020-03-09Exp: 2024-11-19→ Common Stock (14,291 underlying) - Award
Stock Options
2020-03-09+10,663→ 10,663 totalExercise: $11.43From: 2020-03-09Exp: 2025-01-15→ Common Stock (10,663 underlying) - Award
Stock Options
2020-03-09+119,667→ 119,667 totalExercise: $12.04From: 2020-03-09Exp: 2025-11-10→ Common Stock (119,667 underlying) - Award
Stock Options
2020-03-09+35,544→ 35,544 totalExercise: $10.70Exp: 2026-03-01→ Common Stock (35,544 underlying) - Award
Stock Options
2020-03-09+56,275→ 56,275 totalExercise: $6.44Exp: 2029-01-01→ Common Stock (56,275 underlying)
Footnotes (8)
- [F1]Received in or in connection with the merger of Foamix Pharmaceuticals Ltd. ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo Therapeutics Inc. ("Menlo"), in exchange for Foamix equity securities, as further described in the Form 4 filed by the Reporting Person on the date hereof in respect of the Reporting Person's interests in Foamix equity securities. The Reporting Person also received certain contingent stock rights which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo, or related contractual interests, either of which may entitle the Reporting Person to certain additional Menlo equity securities or the adjustment of certain Menlo equity securities, all as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020.
- [F2]Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo.
- [F3]The ordinary shares underlying this option vest over a period of four years (25% on March 1, 2017 and 6.25% every three months thereafter) ending March 31, 2020.
- [F4]The ordinary shares underlying this option vest over a period of four years (25% on January 1, 2018 and 6.25% every three months thereafter) ending March 31, 2021.
- [F5]The ordinary shares underlying this option vest over a period of four years (25% on August 8, 2018 and 6.25% every three months thereafter) ending September 30, 2021.
- [F6]The ordinary shares underlying this option vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending March 31, 2022.
- [F7]The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2020 and 6.25% every three months thereafter) ending March 31, 2023.
- [F8]The ordinary shares underlying this option vest over a period of four years (25% on March 31, 2021 and 6.25% every three months thereafter) ending March 31, 2024.
Documents
Issuer
Menlo Therapeutics Inc.
CIK 0001566044
Entity typeother
Related Parties
1- filerCIK 0001727727
Filing Metadata
- Form type
- 4
- Filed
- Mar 10, 8:00 PM ET
- Accepted
- Mar 11, 5:56 PM ET
- Size
- 30.4 KB